Niraparib demonstrated clinically relevant activity among women with heavily pretreated ovarian cancer, particularly those with homologous recombination deficiency-positive, platinum-sensitive disease, according…
Browsing: Acute Lymphoblastic Leukemia
Data from largest population study to date help identify at-risk individuals, could inform screening initiatives Published on: August 08, 2019 (WASHINGTON, August 8, 2019) — New…
Findings may guide decisions about which patients will benefit most from treatment with sorafenib Advanced hepatocellular carcinoma (HCC) is commonly…
TAGRISSO is the only medicine demonstrating statistically-significant overall survival benefit in this setting. Also increased the time patients with central…
Adjuvant chemoradiotherapy improved overall survival for women with locally advanced endometrial cancer compared with radiation alone, a post-hoc analysis of…
NEW YORK — While new drugs for cancer are helping patients fight the disease, they also produce side effects that…
Niraparib demonstrated clinically relevant activity among women with heavily pretreated ovarian cancer, particularly those with homologous recombination deficiency-positive, platinum-sensitive disease, according…
TORONTO, CANADA / ACCESSWIRE / AUGUST 6, 2019 / Soricimed Biopharma Inc. (“Soricimed”), a clinical-stage pharmaceutical company developing first-in-class, targeted cancer therapeutics, announced…
– Milestone represents the first patient dosed with UltraCAR-T targeting solid tumors – First-in-class investigational therapy using autologous CAR-T cells…
— Enhanced survival outcomes in DKK1-high gastroesophageal junction and gastric cancer patients – — DKK1-high biomarker enables future patient selection –…
Early detection of HPV can prevent various forms of cancer in both men and women, including gay, transgender, and HIV-positive…
July 2, 2019 San Diego Supercomputer Center Researchers Find Novel Diagnosis Method  The invasive and expensive diagnosis process of…
Saad Usmani, MD, Chief, Plasma Cell Disorders Program, Hematologic Malignancies, Levine Cancer Institute/Atrium Health, UNC Chapel Hill School of Medicine,…
Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center explains…
Naiyer Rizvi, MD Price Family Professor of Medicine and Director of Thoracic Oncology, Co-Director of Cancer Immunotherapy, Columbia Irving Medical…
Paul Richardson, MD, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma, Institute Physician, Harvard Medical School considers…
Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology addresses the policies proposed to drig pricing.
Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology explains the role of CDK 4/6 inhibitors in…
Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology shares the results of the ImPassion130, a phase…
Daneng Li, MD, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, Liver Program Disease Team Lead, City of…
New York, NY, June 28, 2019 – Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug…
Lori A. Leslie, MD, Hematologist-Oncologist, Lymphoma Department, John Theurer Cancer Center, Hackensack Meridian Health discusses how impactful CAR-T cell therapy…
Pasi A Jänne, MD, Director, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Senior Physician, Professor of…
Dr. Lowell Hart, MD, Director of Research, Florida Cancer Specialists and Research Institute explains the inhibitors currently being tested for…
Martin E. Gutierrez, MD Director, Phase I Program, Co-Chair of Thoracic Oncology, John Theurer Cancer Center and Hackensack Meridian Health…
Martin E. Gutierrez, MD Director, Phase I Program, Co-Chair of Thoracic Oncology, John Theurer Cancer Center and Hackensack Meridian Health…
Philadelphia, PA (June 4, 2019) – Oncoceutics, Inc. announced a publication in the Journal for ImmunoTherapy of Cancerdemonstrating ONC201 immunostimulatory activity…
Imane El Dika, MD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center explains the role of immuno-oncology (I-O) in the…
Kim Chi MD, Medical Oncologist, Senior Scientist at the BC Cancer Agency discusses upcoming prostate cancer PARP inhibitor trials and…
Harold A. Burstein, M.D, discusses guideline updates on integration results from TAILORx. Use of Biomarkers to Guide Decisions on Adjuvant…
Thomas Yau MD, MBBS Of University of Hong Kong Discusses Nivolumab + Ipilimumab Combo Therapy In Patients with aHCC Results…
Larissa Nekhlyudov MD MPH Of Brigham & Womens Hospital/Dana-Farber Cancer Institute, Harvard Medical School Discusses Bringing Primary Physician Back Into…
Geraldine O’ Sullivan Coyne, MD, discusses the Phase I Trial fo Murlentamab. Background: Membranous expression of AMHRII is found in…
Geraldine O’ Sullivan Coyne, MD, discusses the Phase I Trial of Murlentamab. Background: Membranous expression of AMHRII is found in…
Rod Humerickhouse discusses the Phase 3 CLL14 Trial. Background: The multinational, open-label, phase 3 CLL14 trial compared fixed-duration targeted VenG…
Dr. Cora Sternberg Of Weill Cornell Medicine and NewYork-Presbyterian discusses results of the SAUL study. Background: Atezo, a monoclonal antibody…
Dr. Ronald Shcheff, MD, Of Weill Cornell Medicine and NewYork-Presbyterian discusses the results from KEYNOTE-001. Background: Pembrolizumab (pembro) monotherapy has…
Philadelphia, PA (May 17, 2019) – Oncoceutics, Inc. announced that the latest efficacy data for the use of ONC201 in…
Dr. Sanjay Popat discusses the quality of life for patients using Brigatinib. Background: Results from ALTA-1L (NCT02737501), an international, multicenter…
Dr. Sanjay Popat, PhD, disucsses the Phase 3 ALTA-1L sub-analyses. Background: We report an analysis of BRG vs CRZ in…
Background: MM patients (pts) with high cytogenetic risk have poor outcomes. In CASTOR, D-Vd prolonged progression-free survival (PFS) vs bortezomib…
Alexa Schrock, PhD, of Foundation Medicine Discusses High Microsatellite Instability (MSI-H) in Colorectal Carcinoma Study: Tumor mutational burden is predictive…
Bijal Shah MD Of Moffitt Cancer Center Discusses KTE-X19 Phase 1 Data: Arrived At a Cell Dose, Improved Safety Profile,…
Bijal Shah MD Of Moffitt Cancer Center Discusses KTE-X19 Study Safety: Median Age Is 46, No Impact Seen of Prior…
David M. Cognetti MD @KimmelCancerCtr Of Sidney Kimmel Cancer Center Discusses Photoimmunotherapy (PIT) Phase 2 Study: Multicenter, Open-Label, Study Of…
Marcus Butler, MD of Princess Margaret Cancer Centre discusses the ILLUMINATE 301 A randomized phase 3 study of tilsotolimod in…
Philadelphia, PA (May 7, 2019) – Oncoceutics announced that the US Food and Drug Administration invited the company to present…
The Eon Expert Series: Defying Lung Cancer with Eon + Mark Cuban Why does health tech hurt us more than…
 Philadelphia, PA (May 13, 2019) – Oncoceutics announced today that Michael Chiarella, an industry veteran with more than 20…
UCI team helps uncover how ‘FLASH radiotherapy’ reduces neural cell damage  Irvine, Calif., May 13, 2019 — In hopeful news…